Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (PPCB): 2 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.36 · 3% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for Propanc Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.3M
Cash
—
Quarterly Burn
$1.1M
Runway
—
Revenue
—
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| pop1 program | Preclinical |
| prp | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$25K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 143,212 | $15K |
| marex group plc | 67,724 | $7K |
| sassicaia capital advisers llc | 16,000 | $2K |
| xtx topco ltd | 12,098 | $1K |
Frequently asked questions
How many drug candidates are in Propanc Biopharma, Inc.'s pipeline?
Propanc Biopharma, Inc. (PPCB) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Propanc Biopharma, Inc.'s lead drug candidate?
Propanc Biopharma, Inc.'s most advanced tracked candidate is pop1 program (Preclinical) for Metastatic cancer from solid tumors.
What is Propanc Biopharma, Inc.'s market capitalization?
Propanc Biopharma, Inc.'s market capitalization is approximately $4.3M.
Who is the CEO of Propanc Biopharma, Inc.?
Mr. James Nathanielsz is the chief executive officer of Propanc Biopharma, Inc. (PPCB).
Get the full picture on Propanc Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.